The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma

Haematologica (Impact Factor: 5.81). 01/2006; 90(12):1713-4.
Source: PubMed


Multiple myeloma (MM) is a clonal neoplastic lymphoproliferative disease affecting terminally differentiated B cells i.e. plasma cells characterized by slow proliferation activity and different resistance to apoptosis with latent accumulation of myeloma cells in the bone marrow. This process is induced by failure of normal tissue homeostatic mechanisms. We compared plasma cell proliferation and apoptic indices in various phases of MM and in monoclonal gammophaty of untetermined significance.

Download full-text


Available from: Jiri Minarik,
  • [Show abstract] [Hide abstract]
    ABSTRACT: The proliferation and apoptosis indexes are a significant prognostic factor in multiple myeloma (MM). The objective of the study was to assess the indexes in the course of MM from the point of view of the disease activity and potential clinical use. A sample of 120 patients was studies, of which 49 at diagnosis, 36 in progression and 35 in remission. The proliferation and apoptosis indexes were assessed according to the achieved treatment response and were compared with subsequent progression in patients in remission. The proliferation potential was measured with the propidium-iodide index (PC-PI/CD138), apoptosis was measured with annexine-V (PC-AI/CD138), assessed by the method of flow cytometry. The sample of49 newly diagnosed patients recorded a decrease in PC-PI (M 2.9-2.1, p < 0.0001) and an increase in PC-AI (M 4.7-8.6, p < 0.0001) at remission. Patients without treatment response showed no difference in PC-PI (p = NS), while PC-AI decreased (M 6.2-3.9, p = 0.004). The sample of36 patients in MM progression with treatment response recorded a decrease in PC-PI (M 2.9-2.2, p < 0.0001) and an increase in PC-AI (M 4.6-8.8, p < 0.019). There was no difference in any of the indicators (p = NS) in cases with zero treatment response. 35 patients in remission with developing progression recorded an increase in PC-PI (M 2.3-2.7, p < 0.0001) and a decrease in PC-AI (M 8.3-4.2, p < 0.0001). The study has shown that monitoring PC-PI and PC-AI in the course of different phases of MM is beneficial from the point of view of the assessment of changes in the proliferation activity and the degree of apoptosis of myeloma cells. Monitoring the two parametres allows for timely prediction of disease progression.
    Vnitr̆ní lékar̆ství 01/2008; 54(1):31-5.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess the outcome of the measurement of apoptotic index in myeloma patients treated by conventional chemotherapy and novel drugs with biological mechanism of action, thalidomide and bortezomib. In a cohort of 189 patients with newly diagnosed multiple myeloma from November 1997 through February 2008, we assessed the prognostic significance of plasma cell apoptotic index (PC-AI) using annexin-V. The whole group was subsequently divided according to treatment approach (conventional chemotherapy only vs. inclusion of novel drugs, thalidomide and bortezomib), and curves of overall survival were constructed. In the whole group (n = 189), low levels of PC-AI <4.5% significantly separated patients with unfavorable prognosis (median OS 16 vs. 38 months, P = 0.004). In patients treated with conventional chemotherapy only (n = 139) the results were similar (median OS 10 vs. 25 months, P = 0.02), and the apoptotic index maintained its significance even within the group of 50 patients treated also with novel drugs (median OS 30 vs. 54 months, P = 0.027). PC-AI was found to be independent on both Durie-Salmon staging system and the International Prognostic Index. Presented results suggest the use of apoptotic index by flow cytometry measurement as a fast and accessible method for prognostic stratification of myeloma patients in routine practice.
    European Journal Of Haematology 08/2009; 83(6):528-34. DOI:10.1111/j.1600-0609.2009.01321.x · 2.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In a group of 310 patients with multiple myeloma (MM) we assessed the proliferative (PC-PI) and apoptotic indices (PC-AI). Patients were divided according to the disease state, i.e. at the time of diagnosis, in relapse, and in MM remission. We assessed the behavior of both indices with respect to therapy response and activity of the disease. In patients who reached remission, there was a significant decrease of PC-PI together with an increase of PC-AI in comparison with initial measurements. In non-responders, there was a reverse trend with increasing PC-PI and decreasing PC-AI. The values of PC-PI and PC-AI in residual myeloma population were similar regardless of treatment, i.e. in patients treated using conventional chemotherapy and after high-dosed chemotherapy with autologous stem cell transplant. Patients in long-lasting remission phase maintained stable low values of PC-PI with high PC-AI without a significant change, whereas in the group of progressing/relapsing patients, there was a significant increase of PC-PI together with a decrease of PC-AI. Our results suggest that longitudinal measurement of proliferative and apoptotic indices in MM plasmocytes helps to estimate the behavior of the tumor population and may thus become a convenient auxiliary parameter for prognosis and a targeted, individualized treatment approach.
    Leukemia & lymphoma 10/2009; 50(12):1983-91. DOI:10.3109/10428190903291070 · 2.89 Impact Factor
Show more